MK-7339-010 - A Phase 3, Randomized Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy (KEYLYNK-010)

September 30, 2019
https://clinicaltrials.gov/ct2/show/NCT03834519
Cancer - Prostate
Principal Investigator: Clara Hwang, MD

Castration-resistant

Prostate

Enzalutamide

Abiraterone

MK-7339-010

KEYNOTE-010

Open